Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019.
Ananworanich J, Mogg R, Dunne MW, Bassyouni M, David CV, Gonzalez E, Rogalski-Salter T, Shih H, Silverman J, Medema J, Heaton P. Ananworanich J, et al. Among authors: gonzalez e. Clin Infect Dis. 2022 Aug 24;75(1):e473-e481. doi: 10.1093/cid/ciab813. Clin Infect Dis. 2022. PMID: 34523673 Free PMC article. Clinical Trial.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Gottlieb RL, et al. N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22. N Engl J Med. 2022. PMID: 34937145 Free PMC article. Clinical Trial.
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G; SOURCE study group. Wechsler ME, et al. Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Lancet Respir Med. 2022. PMID: 35364018 Clinical Trial.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Evaluating the Utility of Initial Exams in Retinopathy of Prematurity: Proposal of FIRST-ROP Algorithm for a Medium-Risk Cohort.
Altamirano F, Yuan M, Hoyek S, Hu D, Abidi M, Chaaya C, De Bruyn H, Fulton A, Mantagos IS, Wu C, Gise R, Gonzalez E, VanderVeen DK, Patel NA. Altamirano F, et al. Among authors: gonzalez e. Ophthalmology. 2025 Jan 8:S0161-6420(25)00005-3. doi: 10.1016/j.ophtha.2025.01.004. Online ahead of print. Ophthalmology. 2025. PMID: 39793656
Diagnostic Performance of Two Different Techniques to Quantify CMV-Specific Cell-Mediated Immunity in Intermediate-Risk Seropositive Kidney Transplant Recipients.
Fernández-Ruiz M, Nuévalos M, Rodríguez-Goncer I, García-Ríos E, Ruiz-Merlo T, Redondo N, Trujillo H, González E, Polanco N, Caso JM, Aparicio-Minguijón E, López-Medrano F, San Juan R, Andrés A, Pérez-Romero P, Aguado JM. Fernández-Ruiz M, et al. Among authors: gonzalez e. Transpl Infect Dis. 2025 Jan 10:e14437. doi: 10.1111/tid.14437. Online ahead of print. Transpl Infect Dis. 2025. PMID: 39791950
A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms.
McSwiggen DT, Liu H, Tan R, Agramunt Puig S, Akella LB, Berman R, Bretan M, Chen H, Darzacq X, Ford K, Godbey R, Gonzalez E, Hanuka A, Heckert A, Ho JJ, Johnson SL, Kelso R, Klammer A, Krishnamurthy R, Li J, Lin K, Margolin B, McNamara P, Meyer L, Pierce SE, Sule A, Stashko C, Tang Y, Anderson DJ, Beck HP. McSwiggen DT, et al. Among authors: gonzalez e. Elife. 2025 Jan 9;12:RP93183. doi: 10.7554/eLife.93183. Elife. 2025. PMID: 39786807 Free PMC article.
3,119 results